Propanc Biopharma Inc (PPCB)

$2.87 -5.13 (-64.13%)
Market Cap 155,000.00
Revenue (ttm) 0.00
Net Income (ttm) -1.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 489,547
Avg Vol 2,732
Day's Range N/A - N/A
Shares Out 19,000.00
Stochastic %K 94%
Beta 2.78
Analysts Strong Buy
Price Target $12.50

Company Profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the r...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9882 0780
Fax: 61 3 9882 9969
Address:
302, 6 Butler Street, Camberwell, Australia
Mjv22101
Mjv22101 Mar. 31 at 4:31 PM
$PPCB - I wonder how they raised their 30 million dollars over the years? Taking money from retail investors using dilution and rs tactics is criminal behavior. I hope the sec gets involved, but I won’t hold my breath. IMO stay away from this…. Not financial advice.
0 · Reply
WaveRider666
WaveRider666 Mar. 31 at 11:53 AM
$PPCB - PPCB IR reported to the SEC for constantly pumping this toxic dilution scam on stocktwits.
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 30 at 6:54 PM
$PPCB Our latest research collaboration also expands the scope of PRP into new areas, including the evaluation of senescence-modulating, or anti-aging, approaches. By targeting cellular processes linked to aging and disease progression, we aim to better understand how PRP could address not only cancer, but also chronic conditions such as fibrosis. This reflects the broader potential of our platform to impact multiple high-need disease areas. At the same time, we are preparing to advance PRP into a planned Phase 1b First-In-Human study this year. We believe this combination of scientific expansion and clinical progress represents an important step forward, and we’re excited about what comes next.
0 · Reply
MikiTrader
MikiTrader Mar. 28 at 5:23 AM
$PPCB It’s such a trash chart that I lost any motivation to even short it before looking at anything else.
0 · Reply
ALLEGEDLY1
ALLEGEDLY1 Mar. 27 at 9:05 PM
$XXII $ELAB $IPW $IVF $PPCB huge win on ELAB
0 · Reply
supermanme
supermanme Mar. 27 at 4:23 PM
$PPCB wait until it reaches .08?
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 26 at 10:01 PM
$PPCB Our collaboration with leading academic institutions has translated into a growing intellectual property portfolio. To date, this work has supported the development of four patent families, alongside peer-reviewed publications and scientific presentations that continue to strengthen the underlying validation of our approach. The new agreement will focus in part on generating additional data to support recently filed fibrosis and cancer-related patent applications, reinforcing our strategy to expand and protect the potential applications of PRP. Building a strong IP position is a key step in long-term value creation, particularly as we continue to advance toward clinical development.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 26 at 9:59 PM
$PPCB We’ve signed our fifth research agreement with the Universities of Jaén and Granada, marking over 17 years of continuous collaboration. This long-term partnership has been a core part of our scientific development, supporting multiple research programs and contributing to the advancement of our PRP technology. Under this new multi-year agreement, the focus will be on advancing key experiments to support recently filed patent applications, as well as evaluating new approaches to target cancer and other chronic conditions. This continuity is important. It reflects not just ongoing research, but a sustained effort to build and validate the scientific foundation behind our platform over time.
0 · Reply
ALLEGEDLY1
ALLEGEDLY1 Mar. 26 at 12:26 AM
Back to back major gain swings and I have a new elite 8 looking for my next… I love mixing a technical trade with speculation so if you have any useful DD POST BELOW. (the more bears the better; that usually means its squeeze time) $XXII $ELAB $IPW $IVF $PPCB part 2 with the last 3 coming.
0 · Reply
wummly
wummly Mar. 25 at 6:19 PM
$PPCB on my watch …..has potential
0 · Reply
Latest News on PPCB
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Mar 24, 2026, 8:45 AM EDT - 12 days ago

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Mar 12, 2026, 8:45 AM EDT - 24 days ago

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Mar 10, 2026, 8:45 AM EDT - 26 days ago

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Mar 3, 2026, 8:45 AM EST - 4 weeks ago

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Feb 18, 2026, 8:45 AM EST - 6 weeks ago

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Feb 5, 2026, 8:45 AM EST - 2 months ago

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Jan 27, 2026, 8:45 AM EST - 2 months ago

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Jan 20, 2026, 8:45 AM EST - 2 months ago

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Jan 15, 2026, 8:45 AM EST - 2 months ago

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Propanc Biopharma Provides Shareholder Update

Jan 13, 2026, 8:45 AM EST - 2 months ago

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Dec 22, 2025, 7:00 AM EST - 3 months ago

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Dec 4, 2025, 8:45 AM EST - 4 months ago

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Dec 1, 2025, 8:45 AM EST - 4 months ago

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Nov 17, 2025, 8:45 AM EST - 4 months ago

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Nov 10, 2025, 8:45 AM EST - 5 months ago

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Nov 4, 2025, 7:00 AM EST - 5 months ago

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 5:45 PM EDT - 6 months ago

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 8:45 AM EDT - 6 months ago

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Oct 7, 2025, 8:45 AM EDT - 6 months ago

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Sep 17, 2025, 8:45 AM EDT - 7 months ago

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Sep 2, 2025, 9:00 AM EDT - 7 months ago

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Aug 19, 2025, 8:30 AM EDT - 8 months ago

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Aug 14, 2025, 11:00 PM EDT - 8 months ago

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Mjv22101
Mjv22101 Mar. 31 at 4:31 PM
$PPCB - I wonder how they raised their 30 million dollars over the years? Taking money from retail investors using dilution and rs tactics is criminal behavior. I hope the sec gets involved, but I won’t hold my breath. IMO stay away from this…. Not financial advice.
0 · Reply
WaveRider666
WaveRider666 Mar. 31 at 11:53 AM
$PPCB - PPCB IR reported to the SEC for constantly pumping this toxic dilution scam on stocktwits.
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 30 at 6:54 PM
$PPCB Our latest research collaboration also expands the scope of PRP into new areas, including the evaluation of senescence-modulating, or anti-aging, approaches. By targeting cellular processes linked to aging and disease progression, we aim to better understand how PRP could address not only cancer, but also chronic conditions such as fibrosis. This reflects the broader potential of our platform to impact multiple high-need disease areas. At the same time, we are preparing to advance PRP into a planned Phase 1b First-In-Human study this year. We believe this combination of scientific expansion and clinical progress represents an important step forward, and we’re excited about what comes next.
0 · Reply
MikiTrader
MikiTrader Mar. 28 at 5:23 AM
$PPCB It’s such a trash chart that I lost any motivation to even short it before looking at anything else.
0 · Reply
ALLEGEDLY1
ALLEGEDLY1 Mar. 27 at 9:05 PM
$XXII $ELAB $IPW $IVF $PPCB huge win on ELAB
0 · Reply
supermanme
supermanme Mar. 27 at 4:23 PM
$PPCB wait until it reaches .08?
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 26 at 10:01 PM
$PPCB Our collaboration with leading academic institutions has translated into a growing intellectual property portfolio. To date, this work has supported the development of four patent families, alongside peer-reviewed publications and scientific presentations that continue to strengthen the underlying validation of our approach. The new agreement will focus in part on generating additional data to support recently filed fibrosis and cancer-related patent applications, reinforcing our strategy to expand and protect the potential applications of PRP. Building a strong IP position is a key step in long-term value creation, particularly as we continue to advance toward clinical development.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 26 at 9:59 PM
$PPCB We’ve signed our fifth research agreement with the Universities of Jaén and Granada, marking over 17 years of continuous collaboration. This long-term partnership has been a core part of our scientific development, supporting multiple research programs and contributing to the advancement of our PRP technology. Under this new multi-year agreement, the focus will be on advancing key experiments to support recently filed patent applications, as well as evaluating new approaches to target cancer and other chronic conditions. This continuity is important. It reflects not just ongoing research, but a sustained effort to build and validate the scientific foundation behind our platform over time.
0 · Reply
ALLEGEDLY1
ALLEGEDLY1 Mar. 26 at 12:26 AM
Back to back major gain swings and I have a new elite 8 looking for my next… I love mixing a technical trade with speculation so if you have any useful DD POST BELOW. (the more bears the better; that usually means its squeeze time) $XXII $ELAB $IPW $IVF $PPCB part 2 with the last 3 coming.
0 · Reply
wummly
wummly Mar. 25 at 6:19 PM
$PPCB on my watch …..has potential
0 · Reply
PennyStalker1104
PennyStalker1104 Mar. 24 at 9:57 PM
$LNKS offering closed. Sitting at the bottom and needing a push upwards. Help us out!! 💰 $WNW $LBGJ $WGRX $PPCB
1 · Reply
Stock_Catcher
Stock_Catcher Mar. 24 at 12:45 PM
$PPCB Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 23 at 2:29 PM
$PPCB Innovation in pancreatic cancer represents both a critical medical need and a significant market opportunity. The global pancreatic cancer treatment segment already represents a $3B+ market, reflecting the urgent demand for more effective therapies. PRP, the lead candidate under development at Propanc Biopharma, is designed to target cancer stem cells and other biological mechanisms associated with recurrence and metastasis, areas where current therapies often struggle to deliver durable results. With preclinical validation in place and preparations underway for our upcoming human study, we believe the program is entering an important phase of development. We look forward to sharing further milestones as PRP continues progressing toward the clinic.
0 · Reply
HuanLee
HuanLee Mar. 23 at 8:54 AM
$PPCB
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 20 at 6:02 PM
$PPCB Advancing a new therapy into human clinical testing requires coordinated progress across science, manufacturing, and regulatory preparation. As our Director of Research and Development, Dr. Ralf Brandt, explained: “Establishing and validating our PK method for the First-In-Human study is one of three key activities in preparation for this milestone, alongside GMP manufacturing of PRP and the clinical trial application for the study.” Our collaboration with FyoniBio represents one of these important steps as we continue building the analytical and operational framework required to support the upcoming clinical program for PRP. As Propanc aligns its manufacturing, regulatory, and analytical work, we take coordinated progress toward entering human trials. These preparations are what ultimately enable future value‑creating clinical milestones.
0 · Reply
WaveRider666
WaveRider666 Mar. 20 at 11:58 AM
$PPCB - I see $PPCB IR is back, pumping the Hell out of this endlessly toxic diluting POS. Don't listen to the propaganda. The long term chart tells you everything you need to know about this scam. ps - learn to trade Futures and then you'll never want to touch these toxic diluting stinky pinkies ever again!
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 19 at 8:06 PM
$PPCB As we move closer to initiating our Phase 1b First-In-Human study, establishing the right analytical capabilities is an essential part of the development process. Through our collaboration with FyoniBio, we are developing a liquid chromatography–mass spectrometry (LC-MS) pharmacokinetics assay designed to quantify PRP and its analytes in patient serum over time. The method is expected to detect concentrations with a sensitivity of at least 0.1 µg/mL, allowing researchers to closely track the therapy following administration. These measurements will help our research team understand how PRP behaves in the body while monitoring patient response throughout the clinical study. Developing a sensitive PK assay is essential for generating reliable data once the trial begins. These technical foundations help support stronger clinical outcomes down the line.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Mar. 19 at 7:35 PM
$PPCB Conventional treatments for aggressive cancers such as Pancreatic Cancer often face the same obstacles: toxicity, resistance, and limited long-term effectiveness. PRP is being developed with a different objective. Our proenzyme therapy is designed to influence malignant cells to differentiate while potentially increasing tumor sensitivity to standard chemotherapy. By addressing biological drivers linked to metastasis and recurrence, this approach may complement existing treatment strategies. After more than 17 years of research and development, our focus at Propanc Biopharma is now on translating this scientific work into clinical progress. As we move closer to human trials, we remain committed to disciplined execution and transparent updates.
1 · Reply
KOWALSK1
KOWALSK1 Mar. 18 at 6:54 AM
0 · Reply
KOWALSK1
KOWALSK1 Mar. 17 at 10:45 AM
$PPCB ✅️ BUY ZONE 0.14 to 0.11 ✋️ RISK BELOW 0.09 💲PT. 0.16 0.23 0.30 0.34 0.47 + UP Follow for more
0 · Reply
supermanme
supermanme Mar. 16 at 5:58 PM
$PPCB gaining momentum
0 · Reply
Wubai
Wubai Mar. 16 at 5:49 AM
$PPCB Sometimes you strike gold by digging through the trash—this one reeks, but I’m going for it!🤣🤣
1 · Reply